Cover Image
市場調查報告書

MediPoint:照護現場 (POC) 診斷 - 全球市場的分析與預測

MediPoint: Point of Care Diagnostics - Global Analysis and Market Forecasts

出版商 GlobalData 商品編碼 358873
出版日期 內容資訊 英文 186 Pages
訂單完成後即時交付
價格
Back to Top
MediPoint:照護現場 (POC) 診斷 - 全球市場的分析與預測 MediPoint: Point of Care Diagnostics - Global Analysis and Market Forecasts
出版日期: 2016年03月01日 內容資訊: 英文 186 Pages
簡介

就地檢驗 (POCT) ,是體外診斷 (IVD) 中尤其成長快速的領域之一。

本報告提供全球照護現場 (POC) 診斷市場相關調查分析,現狀與未來發展預測,競爭情形與市場佔有率,主要的高成長市場,未滿足需求,新興技術,影響要素,課題及障礙等系統性資訊。

第1章 目錄

第2章 簡介

第3章 產業概要

  • 照護現場 (POC) 診斷概要
  • 檢驗趨勢
  • M&A,主要的夥伴關係

第4章 未滿足需求

  • 複數的被檢物質的檢測
  • 側流技術的靈敏度
  • 分析相關品質
  • 心肌缺血的標記
  • 資料管理
  • 以POC診斷削減抗生素的使用
  • 成本效益與償付
  • 產業和醫生間的分歧

第5章 推動市場要素與阻礙

  • 推動因素
  • 障礙

第6章 競爭評估

  • 企業佔有率分析
  • 企業策略趨勢
  • 主要企業
    • Abbott Diagnostics
    • Akers Bioscience
    • Alere
    • Beckman Coulter
    • BioMerieux
    • Chembio Diagnostics
    • EKF Diagnostics
    • Meridian Bioscience
    • OraSure Technologies
    • Quidel
    • Radiometer Medical
    • Response Biomedical
    • Roche Diagnostics
    • Siemens Healthcare
    • Trinity Biotech
    • 其他

第7章 開發平台評估

  • 概要
  • 開發平台簡介

第8章 市場預測

  • 各市場部門
  • 各地區

第9章 附錄

圖表

目錄
Product Code: GDME0221MAR

Point-of-care testing (POCT), as known as bedside/near-patient testing is one of the most rapidly growing areas in IVD. Systems that are categorized as POC include the following -

  • Disposable systems or devices, which vary from reagent test strips for a single analyte to multi-analyte reagent strips
  • Small analyzers, usually hand-held devices
  • Desktop analyzers are larger and include systems designed for use in clinics or small laboratories.

POCT may be performed in a variety of locations such as in secondary care including emergency departments, ambulance service, hospital wards, and intensive treatment units; and increasingly in the community and primary care including general practice (GP), health and community centers.

  • $2 billion in annual global sales and growth rate of 5.3% during the forecast period; the emerging markets: China, India and Brazil, are expected to show the fastest growth.
  • A number of factors, such as the increasing prevalence of infectious diseases in developing countries, the rising incidences of lifestyle diseases such as cardiac diseases and diabetes, the rising usage of home-based POC devices, expansion of test menu, and advancements in molecular testing and lab-on-chip technology are stimulating the demand for POC testing.
  • The rate of POC testing adoption will be moderated by the requirement for regulatory compliance, the pressure to control cost, and the need to demonstrate clear clinical-cost benefits of POC testing over central laboratory testing.

Highlights

Key Questions Answered

  • What is the current and future POC diagnostics market outlook in the developed and emerging markets? What trends are affecting the global market?
  • What is the competitive landscape and market share of major players in the POC space across different regions?
  • What are the key, high growth markets that IVD manufacturers should expand into? Which market segments are growing the fastest?
  • What are the unmet needs with the POC tests currently on the market? How will emerging technologies such as molecular POC assays fulfil these unmet needs?
  • What are the key factors influencing a physician to use POC tests? What is physician perception and market outlook of POC devices?
  • What are the challenges and barriers that have hindered widespread adoption of POC devices?

Scope

  • Competitive assessment: Currently marketed POC products and evolving competitive landscape
  • In-depth analysis of unmet needs and adoption trends of different POC devices
  • Insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications
  • Pipeline analysis: Emerging products and technologies.
  • Annualized total POC diagnostics market revenue by segment and market outlooks by country from 2012-2021.
  • Other key topics covered include strategic competitive assessment, market characterization, identification of unmet needs, market dynamics, and implications of the emerging technologies on the market.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
  • Develop business strategies by understanding the trends shaping and driving the global market
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Track device sales in the global market from 2012-2021
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. POC Diagnostics Overview
  • 3.2. Test Trends
    • 3.2.1. Cardiac Markers POC Testing
    • 3.2.2. Female Fertility and Pregnancy POC Testing
  • 3.3. Mergers, Acquisitions, and Key Partnerships

4. Unmet Needs

  • 4.1. Detection of Multiple Analytes
  • 4.2. Sensitivity of Lateral Flow Technology
  • 4.3. Analytical Quality
  • 4.4. Markers for Myocardial Ischemia
  • 4.5. Data Management
  • 4.6. POC Diagnostics to Reduce Usage of Antibiotics
  • 4.7. Cost-Effectiveness and Reimbursement
  • 4.8. Gap between Physicians and Manufacturers

5. Market Drivers and Barriers

  • 5.1. Drivers
    • 5.1.1. Fast Turnaround Time
    • 5.1.2. POC Molecular Testing Driving Infectious Disease POCT
    • 5.1.3. Increasing Adoption of Cardiac Marker POCT
    • 5.1.4. Expansion POC Testing Menu
    • 5.1.5. Expansion of the Home-Testing Market
    • 5.1.6. CLIA Waived Status for POCT
    • 5.1.7. Rising Prevalence of Diseases
  • 5.2. Barriers
    • 5.2.1. Management of POCT
    • 5.2.2. Competition with Laboratory Tests
    • 5.2.3. Regulatory Compliance
    • 5.2.4. Medical Device Excise Tax

6. Competitive Assessment

  • 6.1. Company Share Analysis
    • 6.1.1. Global
    • 6.1.2. US
    • 6.1.3. Europe
    • 6.1.4. Asia-Pacific
  • 6.2. Trends in Corporate Strategy
  • 6.3. Major Players
    • 6.3.1. Abbott Diagnostics
    • 6.3.2. Akers Bioscience
    • 6.3.3. Alere
    • 6.3.4. Beckman Coulter
    • 6.3.5. BioMerieux
    • 6.3.6. Chembio Diagnostics
    • 6.3.7. EKF Diagnostics
    • 6.3.8. Meridian Bioscience
    • 6.3.9. OraSure Technologies
    • 6.3.10. Quidel
    • 6.3.11. Radiometer Medical
    • 6.3.12. Response Biomedical
    • 6.3.13. Roche Diagnostics
    • 6.3.14. Siemens Healthcare
    • 6.3.15. Trinity Biotech
    • 6.3.16. Other Companies

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Pipeline Profiles
    • 7.2.1. Cardiac Markers POCT
    • 7.2.2. Female Fertility and Pregnancy POCT
    • 7.2.3. Hematology POCT
    • 7.2.4. Infectious Disease POCT
    • 7.2.5. Immunochemistry POCT Analyzers

8. Market Outlook

  • 8.1. By Market Segment
    • 8.1.1. Global Overview
    • 8.1.2. Cardiac Markers POCT
    • 8.1.3. Female Fertility and Pregnancy POCT
    • 8.1.4. Hematology POCT
    • 8.1.5. Infectious Disease POCT
    • 8.1.6. Immunochemistry POCT Analyzers
  • 8.2. By Geography
    • 8.2.1. Global Overview
    • 8.2.2. US
    • 8.2.3. France
    • 8.2.4. Germany
    • 8.2.5. Italy
    • 8.2.6. Spain
    • 8.2.7. UK
    • 8.2.8. Japan
    • 8.2.9. China
    • 8.2.10. India
    • 8.2.11. Brazil

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Report Methodology
    • 9.3.1. Overview
    • 9.3.2. Coverage
    • 9.3.3. Secondary Research
    • 9.3.4. Forecasting Methodology
    • 9.3.5. Primary Research - Key Opinion Leader Interviews
    • 9.3.6. Primary Research - Physician and Industry Interviews
    • 9.3.7. Expert Panel Validation
  • 9.4. Physicians and Specialists Included in This Study
  • 9.5. About the Authors
    • 9.5.1. Analysts
    • 9.5.2. Tyler Fletcher, Global Head of Medical Devices
  • 9.6. About MediPoint
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Advantages and Disadvantages of POCT
  • Table 2: Global Troponin POCT Volume (thousands) Forecast by Country, 2012-2021
  • Table 3: Global B-type Natriuretic Peptide POCT Volume (thousands) Forecast by Country, 2012-2021
  • Table 4: Global Follicle-Stimulating Hormone POCT Volume Forecast by Country, 2012-2021
  • Table 5: Global Luteinizing Hormone POCT Volume (thousands) Forecast by Country, 2012-2021
  • Table 6: Global Human Chorionic Gonadotropin POCT Volume (thousands) Forecast by Country, 2012-2021
  • Table 7: Mergers, Acquisitions, and Key Partnerships, 2012-2016
  • Table 8: Company Profile - Abbott Diagnostics
  • Table 9: Abbott Diagnostics' POC Portfolio Assessment, 2015
  • Table 10: SWOT Analysis - Abbott Diagnostics
  • Table 11: Company Profile - Akers Bioscience
  • Table 12: Aker Bioscience's POC Portfolio Assessment, 2015
  • Table 13: SWOT Analysis - Akers Bioscience
  • Table 14: Company Profile - Alere
  • Table 15: Alere's POC Portfolio Assessment, 2015
  • Table 16: SWOT Analysis - Alere
  • Table 17: Company Profile - Beckman Coulter
  • Table 18: Beckman Coulter's POC Portfolio Assessment, 2015
  • Table 19: SWOT Analysis - Beckman Coulter
  • Table 20: Company Profile - BioMerieux
  • Table 21: BioMerieux's POC Portfolio Assessment, 2015
  • Table 22: SWOT Analysis - BioMerieux
  • Table 23: Company Profile - Chembio Diagnostics
  • Table 24: Chembio Diagnostics' POC Portfolio Assessment, 2015
  • Table 25: SWOT Analysis - Chembio Diagnostics
  • Table 26: Company Profile - EKF Diagnostics
  • Table 27: EKF Diagnostics' POC Portfolio Assessment, 2015
  • Table 28: SWOT Analysis - EKF Diagnostics
  • Table 29: Company Profile - Meridian Bioscience
  • Table 30: Meridian Bioscience's POC Portfolio Assessment, 2015
  • Table 31: SWOT Analysis - Meridian Bioscience
  • Table 32: Company Profile - OraSure Technologies
  • Table 33: OraSure Technologies' POC Portfolio Assessment, 2015
  • Table 34: SWOT Analysis - OraSure Technologies
  • Table 35: Company Profile - Quidel
  • Table 36: Quidel's POC Portfolio Assessment, 2015
  • Table 37: SWOT Analysis - Quidel
  • Table 38: Company Profile - Radiometer Medical
  • Table 39: Radiometer Medical's POC Portfolio Assessment, 2015
  • Table 40: SWOT Analysis - Radiometer Medical
  • Table 41: Company Profile - Response Biomedical
  • Table 42: Response Biomedical's POC Portfolio Assessment, 2015
  • Table 43: SWOT Analysis - Response Biomedical
  • Table 44: Company Profile - Roche Diagnostics
  • Table 45: Roche Diagnostics' POC Portfolio Assessment, 2015
  • Table 46: SWOT Analysis - Roche Diagnostics
  • Table 47: Company Profile - Siemens Healthcare
  • Table 48: Siemens Healthcare's POC Portfolio Assessment, 2015
  • Table 49: SWOT Analysis - Siemens Healthcare
  • Table 50: Company Profile - Trinity Biotech
  • Table 51: Trinity Biotech's POC Portfolio Assessment, 2015
  • Table 52: SWOT Analysis - Trinity Biotech
  • Table 53: Other POC Companies in North America, 2015
  • Table 54: Other POC Companies in Europe, 2015
  • Table 55: Other POC Companies in APAC and Other Regions, 2015
  • Table 56: Key Cardiac Markers POCT Pipelines, 2015
  • Table 57: Key Female Fertility and Pregnancy POCT Pipelines, 2015
  • Table 58: Key Hematology POCT Pipelines, 2015
  • Table 59: Key Infectious Disease POCT Pipelines, 2015
  • Table 60: Key Immunochemistry POCT Analyzer Pipelines, 2015
  • Table 61: Global POC Diagnostics Sales Forecast ($m) by Market Segment, 2012-2021
  • Table 62: Cardiac Marker POCT Sales Forecast ($m), 2012-2021
  • Table 63: Fertility and Pregnancy POCT Sales Forecast ($m), 2012-2021
  • Table 64: Hematology POCT Sales Forecast ($m), 2012-2021
  • Table 65: Infectious Disease POCT Sales Forecast ($m), 2012-2021
  • Table 66: Immunochemistry POCT Analyzers Sales Forecast ($m), 2012-2021
  • Table 67: Global POC Diagnostics Sales Forecast ($m) by Country, 2012-2021
  • Table 68: US POC Diagnostics Sales Forecast ($m), 2012-2021
  • Table 69: France POC Diagnostics Sales Forecast ($m), 2012-2021
  • Table 70: Germany POC Diagnostics Sales Forecast ($m), 2012-2021
  • Table 71: Italy POC Diagnostics Sales Forecast ($m), 2012-2021
  • Table 72: Spain POC Diagnostics Sales Forecast ($m), 2012-2021
  • Table 73: UK POC Diagnostics Sales Forecast ($m), 2012-2021
  • Table 74: Japan POC Diagnostics Sales Forecast ($m), 2012-2021
  • Table 75: China POC Diagnostics Sales Forecast ($m), 2012-2021
  • Table 76: India POC Diagnostics Sales Forecast ($m), 2012-2021
  • Table 77: Brazil POC Diagnostics Sales Forecast ($m), 2012-2021
  • Table 78: POC Diagnostics - Primary Call Count by Country

List of Figures

  • Figure 1: Troponin POCT Volume by Country, 2012-2021
  • Figure 2: B-type Natriuretic Peptide POCT Volume by Country, 2012-2021
  • Figure 3: Follicle-Stimulating Hormone POCT Volume by Country, 2012-2021
  • Figure 4: Luteinizing Hormone POCT Volume by Country, 2012-2021
  • Figure 5: Human Chorionic Gonadotropin POCT Volume by Country, 2012-2021
  • Figure 6: Global POC Diagnostics Market, By Company Share, 2015
  • Figure 7: US POC Diagnostics Market, By Company Share, 2015
  • Figure 8: Europe POC Diagnostics Market, By Company Share, 2015
  • Figure 9: APAC POC Diagnostics Market, By Company Share, 2015
  • Figure 10: Global POC Diagnostics Sales Forecast ($m) by Market Segment, 2012-2021
  • Figure 11: Global POC Diagnostics Market Potential by Segment, 2021
  • Figure 12: Cardiac Marker POCT Sales Forecast ($m), 2012-2021
  • Figure 13: Fertility and Pregnancy POCT Sales Forecast ($m), 2012-2021
  • Figure 14: Hematology POCT Sales Forecast ($m), 2012-2021
  • Figure 15: Infectious Disease POCT Sales Forecast ($m), 2012-2021
  • Figure 16: Immunochemistry POCT Analyzers Sales Forecast ($m), 2012-2021
  • Figure 17: Global POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 18: Global POC Diagnostics Market Share Forecast ($m) by Country, 2015 and 2021
  • Figure 19: Global POC Diagnostics Market Potential by Country, 2021
  • Figure 20: US POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 21: US POC Diagnostics Market Revenue Breakdown, by Segment, 2015
  • Figure 22: France POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 23: France POC Diagnostics Market Revenue Breakdown, by Segment, 2015
  • Figure 24: Germany POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 25: Germany POC Diagnostics Market Revenue Breakdown, by Segment, 2015
  • Figure 26: Italy POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 27: Italy POC Diagnostics Market Revenue Breakdown, by Segment, 2015
  • Figure 28: Spain POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 29: Spain POC Diagnostics Market Revenue Breakdown, by Segment, 2015
  • Figure 30: UK POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 31: UK POC Diagnostics Market Revenue Breakdown, by Segment, 2015
  • Figure 32: Japan POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 33: Japan POC Diagnostics Market Revenue Breakdown, by Segment, 2015
  • Figure 34: China POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 35: China POC Diagnostics Market Revenue Breakdown, by Segment, 2015
  • Figure 36: India POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 37: India POC Diagnostics Market Revenue Breakdown, by Segment, 2015
  • Figure 38: Brazil POC Diagnostics Sales Forecast ($m), 2012-2021
  • Figure 39: Brazil POC Diagnostics Market Revenue Breakdown, by Segment, 2015
  • Figure 40: POC Diagnostics - Primary Call Count by Country (N=390)
Back to Top